Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Update

Posted by Donna Armstrong on Jul 24th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 3,571 shares, a decline of 94.5% from the June 30th total of 65,392 shares. Based on an average trading volume of 99,268 shares, the short-interest ratio is presently 0.0 days. Approximately 0.4% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Cuprina Holdings (Cayman) from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Stock Report on CUPR

Cuprina Holdings (Cayman) Stock Performance

Shares of Cuprina Holdings (Cayman) stock traded up $0.03 during trading on Friday, reaching $3.34. The company’s stock had a trading volume of 12,799 shares, compared to its average volume of 1,379,201. The stock has a 50-day moving average of $3.91. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.07. Cuprina Holdings has a one year low of $1.76 and a one year high of $76.00.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last issued its quarterly earnings results on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter.

Cuprina Holdings (Cayman) Company Profile

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.